LENZ Therapeutics director Zach Scheiner resigns from board
Jeff George takes the vacated audit committee seat as LENZ's board shrinks to six members, per an 8-K filed for the June 30, 2026 event.
LENZ Therapeutics, Inc. disclosed in an 8-K that Zach Scheiner notified the company on June 30, 2026 of his resignation as a member of the board of directors and from all committees on which he served, effective immediately.1
The filing states that the resignation did not stem from any dispute or disagreement with the company over its operations, policies or practices.1 The company also said Scheiner had been a valuable board member and thanked him for his service on the board and its committees.1
As a result of the departure, the board voted on June 30, 2026 to reduce its size to six members.1
Following Scheiner's exit, the board appointed Jeff George to its audit committee on June 30, 2026.1 With that change, the audit committee now consists of Shelley Thunen, Frederic Guerard, and Jeff George.1
The report was signed on behalf of LENZ Therapeutics by Chief Financial Officer Daniel Chevallard, dated July 2, 2026. The company is incorporated in Delaware and trades on the Nasdaq Stock Market under the ticker LENZ, with headquarters in Solana Beach, California.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.